Pre-made Ramucirumab biosimilar ( Whole mAb, anti-KDR therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-468
Anti-KDR therapeutic antibody (Pre-made Ramucirumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-KDR therapeutic antibody (Pre-made Ramucirumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||3s34:HL/3s37:HL/3s36:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine|
|Conditions Approved||Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer|
|Conditions Active||Oesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer|
|Conditions Discontinued||Breast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma|
|Development Tech||Dyax Human Phage Display|